Bernd Schollmeier

Are you looking to de-risk your asset's journey to market, secure optimal pricing, or scale your global advisory platform?

I bring over 30 years of C-suite advisory and executive life sciences experience to your high-stakes projects. Having successfully established global market access practices and led over 40 complex due diligence projects, I transform clinical data into robust value propositions. My focus is entirely on driving tangible commercial impact for vaccines, rare diseases, and complex therapeutics.

Global Market Access & Pricing Strategy: Designing commercialisation and launch strategies that withstand rigorous payer scrutiny across European and global markets.

Economic Strategy & Floor Price Governance: Developing international reference pricing (IRP) models and governance frameworks to safeguard asset valuation.

HEOR & RWE Translation: Translating complex clinical endpoints and real-world evidence into clear, compelling payer narratives.

Early-Stage De-risking & NPP: Optimising Target Product Profiles (TPP) and providing precise asset valuations during Phase I–III development.

Interim Leadership & Practice Scaling: Serving as a fractional executive or strategic advisor to build, scale, or lead global market access and advisory platforms.

Commercialisation & Launch Readiness: Spearheading market entry and navigating complex regional frameworks (such as Article 71 KVV in Switzerland or AMNOG in Germany).

Due Diligence & Business Cases: Conducting rigorous strategic assessments for biotechs and pharma firms to validate commercial viability before major investment decisions.

Let focused expertise drive your market access success. We should schedule a detailed discussion to review your pipeline requirements and explore how we can secure your upcoming launches.